Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S.
Tonyali O, et al. Among authors: yildiz r.
Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16.
Onkologie. 2013.
PMID: 24107908